Cargando…

Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales

BACKGROUND: Injecting drug use is a key risk factor, for several infections of public health importance, especially hepatitis B (HBV) and hepatitis C (HCV). In England and Wales, where less than 1% of the population are likely to be injecting drug users (IDUs), approximately 38% of laboratory report...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutton, AJ, Gay, NJ, Edmunds, WJ, Hope, VD, Gill, ON, Hickman, M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1524784/
https://www.ncbi.nlm.nih.gov/pubmed/16762050
http://dx.doi.org/10.1186/1471-2334-6-93
_version_ 1782128845184303104
author Sutton, AJ
Gay, NJ
Edmunds, WJ
Hope, VD
Gill, ON
Hickman, M
author_facet Sutton, AJ
Gay, NJ
Edmunds, WJ
Hope, VD
Gill, ON
Hickman, M
author_sort Sutton, AJ
collection PubMed
description BACKGROUND: Injecting drug use is a key risk factor, for several infections of public health importance, especially hepatitis B (HBV) and hepatitis C (HCV). In England and Wales, where less than 1% of the population are likely to be injecting drug users (IDUs), approximately 38% of laboratory reports of HBV, and 95% of HCV reports are attributed to injecting drug use. METHODS: Voluntary unlinked anonymous surveys have been performed on IDUs in contact with specialist agencies throughout England and Wales. Since 1990 more than 20,000 saliva samples from current IDUs have been tested for markers of infection for HBV, HCV testing has been included since 1998. The analysis here considers those IDUs tested for HBV and HCV (n = 5,682) from 1998–2003. This study derives maximum likelihood estimates of the force of infection (the rate at which susceptible IDUs acquire infection) for HBV and HCV in the IDU population and their trends over time and injecting career length. The presence of individual heterogeneity of risk behaviour and background HBV prevalence due to routes of transmission other than injecting are also considered. RESULTS: For both HBV and HCV, IDUs are at greatest risk from infection in their first year of injecting (Forces of infection in new initiates 1999–2003: HBV = 0.1076 95% C.I: 0.0840–0.1327 HCV = 0.1608 95% C.I: 0.1314–0.1942) compared to experienced IDUs (Force of infection in experienced IDUs 1999–2003: HBV = 0.0353 95% C.I: 0.0198–0.0596, HCV = 0.0526 95% C.I: 0.0310–0.0863) although independently of this there is evidence of heterogeneity of risk behaviour with a small number of IDUs at increased risk of infection. No trends in the FOI over time were detected. There was only limited evidence of background HBV infection due to factors other than injecting. CONCLUSION: The models highlight the need to increase interventions that target new initiates to injecting to reduce the transmission of blood-borne viruses. Although from the evidence here, identification of those individuals that engage in heightened at-risk behaviour may also help in planning effective interventions. The data and methods described here may provide a baseline for monitoring the success of public health interventions.
format Text
id pubmed-1524784
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15247842006-07-29 Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales Sutton, AJ Gay, NJ Edmunds, WJ Hope, VD Gill, ON Hickman, M BMC Infect Dis Research Article BACKGROUND: Injecting drug use is a key risk factor, for several infections of public health importance, especially hepatitis B (HBV) and hepatitis C (HCV). In England and Wales, where less than 1% of the population are likely to be injecting drug users (IDUs), approximately 38% of laboratory reports of HBV, and 95% of HCV reports are attributed to injecting drug use. METHODS: Voluntary unlinked anonymous surveys have been performed on IDUs in contact with specialist agencies throughout England and Wales. Since 1990 more than 20,000 saliva samples from current IDUs have been tested for markers of infection for HBV, HCV testing has been included since 1998. The analysis here considers those IDUs tested for HBV and HCV (n = 5,682) from 1998–2003. This study derives maximum likelihood estimates of the force of infection (the rate at which susceptible IDUs acquire infection) for HBV and HCV in the IDU population and their trends over time and injecting career length. The presence of individual heterogeneity of risk behaviour and background HBV prevalence due to routes of transmission other than injecting are also considered. RESULTS: For both HBV and HCV, IDUs are at greatest risk from infection in their first year of injecting (Forces of infection in new initiates 1999–2003: HBV = 0.1076 95% C.I: 0.0840–0.1327 HCV = 0.1608 95% C.I: 0.1314–0.1942) compared to experienced IDUs (Force of infection in experienced IDUs 1999–2003: HBV = 0.0353 95% C.I: 0.0198–0.0596, HCV = 0.0526 95% C.I: 0.0310–0.0863) although independently of this there is evidence of heterogeneity of risk behaviour with a small number of IDUs at increased risk of infection. No trends in the FOI over time were detected. There was only limited evidence of background HBV infection due to factors other than injecting. CONCLUSION: The models highlight the need to increase interventions that target new initiates to injecting to reduce the transmission of blood-borne viruses. Although from the evidence here, identification of those individuals that engage in heightened at-risk behaviour may also help in planning effective interventions. The data and methods described here may provide a baseline for monitoring the success of public health interventions. BioMed Central 2006-06-08 /pmc/articles/PMC1524784/ /pubmed/16762050 http://dx.doi.org/10.1186/1471-2334-6-93 Text en Copyright © 2006 Sutton et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sutton, AJ
Gay, NJ
Edmunds, WJ
Hope, VD
Gill, ON
Hickman, M
Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title_full Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title_fullStr Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title_full_unstemmed Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title_short Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales
title_sort modelling the force of infection for hepatitis b and hepatitis c in injecting drug users in england and wales
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1524784/
https://www.ncbi.nlm.nih.gov/pubmed/16762050
http://dx.doi.org/10.1186/1471-2334-6-93
work_keys_str_mv AT suttonaj modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales
AT gaynj modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales
AT edmundswj modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales
AT hopevd modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales
AT gillon modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales
AT hickmanm modellingtheforceofinfectionforhepatitisbandhepatitiscininjectingdrugusersinenglandandwales